Charité Entrepreneurship Summit 2012 (updated every week- check back soon)


Since its successful launch in 2007, the Charité Entrepreneurship Summit has become an international forum for participants and speakers coming from various professional backgrounds in medicine, life sciences, and in entrepreneurship.

On April 23-24, 2012, the Stiftung Charité and Kauffman Foundation will hold the fifth “Charité Entrepreneurship Summit” at the Humboldt Carré in Berlin. Once again researchers, clinicians, and doctoral students present fresh ideas and learn from successful entrepreneurs, investors, and business developers.

If you have any further questions, please contact our project manager, Mrs Katharina Stoecker, by telephone +49 30 450570-508 or send us an email.

See some of our confirmed Speakers below. If you want to register for our Summit 2012 click here or take a look at all confirmed speakers.


    Anne Glover

    Chief Executive, Amadeus Capital Partners Ltd, London/UK

    Anne M. Glover is a co-Founder and chief executive of Amadeus Capital Partners Limited, the management company that provides investment services to the Amadeus venture capital funds. Previously she was a member of the investment team at Apax Partners, invested as a business angel, and served as COO at the Virtuality Group plc. In 2004-2005 Anne was chairman of the British Venture Capital Association (BVCA), and currently she is a non-executive director of the UK government's Technology Strategy Board. She holds an MA in Metallurgy and Materials Science from Clare College, Cambridge, and an MA in Public and Private Management from Yale.

    Alexander Osterwalder

    Partner, Business Model Innovator, Geneva Area/Switzerland

    Dr. Alexander Osterwalder works as an independent author, speaker and advisor with a particular focus on business model innovation, strategic management and management innovation.
    Besides his independent activities he is partner at Arvetica, a consulting boutique focusing on the private banking and wealth management industry. His role includes business development and the management of a peer knowledge exchange platform for senior executives in private banking. Before that Dr. Osterwalder founded and ran BusinessModelDesign.com, a consulting boutique active in strategy consulting with a focus on business model innovation. He also helped develop and implement the strategy and business concept of a globally active not for profit network called The Constellation for over one year in Thailand.

    Antoine Papiernik

    Managing Partner, Sofinnova, Paris/France

    He joined Sofinnova Partners in 1997, and was previously with CDC-Innovation, the venture arm of  the Caisse des Dépôts group. Since joining Sofinnova Partners, Antoine has been an initial investor and active board member in public companies like Actelion, Addex, Orexo, NovusPharma, Movetis and Stentys, which went public respectively on the Zürich stock exchange, the Stockholm stock exchange, the Milan Nuovo Mercato, the Belgium Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic) and Fovea (sold to Sanofi Aventis).

    Halle Tecco

    Founder and CEO, Rock Health, San Francisco/USA

    Halle directs Rock Health, the first seed-accelerator for health apps. She works directly with startups, helping them develop sustainable business models and connecting them with strategic partners. She has written for Harvard Business School Publishing, Stanford Social Innovation Review, Glamour.com and Forbes. Halle earned a BS at Case Western Reserve University and her MBA at Harvard Business School.

    Sander van Deventer

    Partner, Forbion Capital Partners, AD Naarden/Netherlands

    Sander van Deventer has extensive experience in translational research with particular emphasis on drug development, and significant regulatory experience with the European Agency for the Evaluation of Medicinal Products (EMEA) and Food and Drug Administration. Sander van Deventer is professor of translational gastroenterology at Leiden University Medical Center and is general partner of Forbion Capital Partners (formerly, ABN AMRO Capital). He is co-founder of the gene therapy company Amsterdam Molecular Therapeutics, and currently holds a part-time position on the company´s board as Chief Scientific Officer. He also holds a board seat at Argos Therapeutics. Dr. van Deventer was trained and board certified in internal medicine and gastroenterology, and received his medical degree and doctor of philosophy from the University of Amsterdam.

    Chuck Wilson

    VP Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research Inc., Basel/ Switzerland.

    Dr. Chuck Wilson serves as the Global Head of Strategic Alliances, leading a group responsible for research partnering at Novartis. Partnering efforts include academic relationships to understand disease processes, biotech collaborations to access drug discovery technologies, and in-licensing of compounds prior to clinical proof-of-concept. Prior to joining Novartis, Chuck founded and led Archemix, a company focused on aptamer therapeutics. Before moving into industry, Chuck was a professor in the Department of Molecular, Cellular, and Developmental Biology at the University of California, Santa Cruz where his group determined the first x-ray structures of aptamers bound to their targets.

Modules

Charité Partnering

Business Speed Dating

Charité Window – Charité researchers discuss: “Future medical needs and potential solutions”

Entrepreneurship Competition

“Medical Business Idea 2012”